Not all evidence is equal: How regulators actually judge nutrition science

One of the biggest disconnects between food brands and regulators is the assumption that any published nutrition research carries equal weight. In reality, regulators apply a strict hierarchy of evidence, assess study design quality, interrogate risk of bias, and evaluate whether the evidence is fit for purpose – not just whether it exists.

Understanding how regulators judge nutrition science isn’t optional if you’re planning health claims, functional positioning, or future-proof product innovation. It’s foundational.

Evidence hierarchies: Why some studies matter more than others

In regulatory decision-making, not all evidence is treated equally. Regulators rely on evidence hierarchies that rank study designs according to how reliably they can demonstrate cause and effect.

At the top sit systematic reviews and meta-analyses, followed by well-designed randomised controlled trials (RCTs). Further down the hierarchy are prospective cohort studies, case-control studies, cross-sectional and mechanistic studies, and animal and in vitro research.

This doesn’t mean lower-level evidence is “bad.” It means it answers different types of questions. Regulators prioritise evidence that can demonstrate causality, not just association or biological plausibility.

Study design differences: What regulators look for

Two studies can investigate the same nutrient and report similar outcomes, yet one may be considered robust and the other essentially unusable for regulatory purposes.

Regulators scrutinise population relevance – whether the study was conducted in healthy adults or clinical populations – alongside the dose and form of the food or nutrient, the comparator or control conditions, the outcome measures used, the duration and exposure, and the statistical power and analysis methods applied.

A short-term pilot study with 15 participants may be useful for hypothesis generation, but it won’t support a health claim. This is why brands often believe the evidence is “there,” while regulators conclude it is insufficient or inconsistent.

Risk of bias: The question regulators always ask

Even a well-designed study can be downgraded if it carries a high risk of bias.

Regulators assess randomisation methods, allocation concealment, blinding of participants and investigators, attrition and missing data, selective outcome reporting, and conflicts of interest. If bias is likely to distort results, the study’s contribution to the evidence base is reduced – sometimes significantly.

This is why industry-funded studies are not automatically dismissed, but they are always examined more closely.

What regulators actually expect from evidence

Regulators aren’t asking for perfection. They’re asking for confidence.

That confidence comes from consistency of findings across multiple studies, replication in different populations and settings, biological plausibility supported by mechanistic data, and clear relevance to the proposed claim wording.

In Australia, Food Standards Australia New Zealand (FSANZ) applies these principles when assessing health claims under the Food Standards Code. Internationally, the same approach is reflected by bodies like the European Food Safety Authority. The framework is consistent: regulators are not convinced by the volume of evidence. They are convinced by quality, coherence, and relevance.

Why brands get caught out

Most regulatory failures don’t happen because there’s no evidence. They happen because evidence was generated after a claim was already conceptualised, studies were selected without assessing regulatory suitability, evidence was over-interpreted beyond what it could actually support, or feasibility wasn’t assessed early enough.

Once packaging is designed or claims are embedded in brand positioning, the cost of getting this wrong escalates quickly.

The strategic advantage of thinking like a regulator

Brands that succeed in regulated nutrition spaces don’t just collect studies – they build evidence strategies. That means understanding which study designs matter before research begins, aligning outcomes with claim intent, identifying gaps early, and avoiding costly rework, relabelling, or reformulation.

At NPR Consulting, this is exactly where we focus: bridging the gap between nutrition science, regulation, and real-world commercial decisions. Because in regulation, evidence doesn’t speak for itself – it has to stand up to scrutiny.

Want to know if your evidence is actually fit for purpose

If you’re unsure whether your current evidence base would hold up under regulatory review, or you’re planning future claims and want to get it right from the start, this is the stage where early advice saves the most time and money.

Download our FREE Food Label Compliance Checklist or get in touch explore how NPR Consulting supports brands with evidence strategy, health claim feasibility, and regulatory alignment.